Cardiomyopathy
After sudden cardiac death, genetic testing may provide answers, identify risks for family
Sudden death from cardiac causes is among the leading causes of death in the United States, yet predicting who might be at high risk remains a difficult task.
Pre-sports participation CV screening most accurate in children aged 12 years or older
When children aged 8 to 15 years were screened for risk for before participating in sports, the diagnostic yield for identifying those at risk was higher in those aged 12 years or older, researchers reported.
‘Across the board’ benefits seen with acoramidis for transthyretin amyloid cardiomyopathy
Acoramidis, an investigational treatment for symptomatic transthyretin amyloid cardiomyopathy, was associated with marked improvements in all-cause mortality and CV-related hospitalizations compared with placebo, data show.
Screening for peripartum cardiomyopathy using AI-enhanced digital stethoscope shows promise
PHILADELPHIA — In the SPEC-AI trial, use of an artificial intelligence-enhanced digital stethoscope doubled the number of cases of peripartum cardiomyopathy identified among pregnant and postpartum women.
Regular marijuana use linked to risk for HF, major adverse heart, brain events
PHILADELPHIA — Two observational studies presented at the American Heart Association Scientific Sessions linked regular marijuana use to elevated risk for HF and elevated risk for major adverse cardiac and cerebrovascular events.
Despite panel support, FDA rejects patisiran for ATTR amyloidosis with cardiomyopathy
The FDA rejected a supplemental new drug application for patisiran to treat cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness.
‘One giant leap for HCM’: Gene therapy may reverse hypertrophic cardiomyopathy
Despite advances made for the treatment and management of hypertrophic cardiomyopathy, the condition remains a debilitating one for many patients, who are often undiagnosed until the disease has progressed.
FDA panel supports patisiran for ATTR amyloidosis with cardiomyopathy
An FDA panel voted 9-3 in favor of expanding approval of patisiran to patients with cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, noting modest benefits but no significant safety concerns.
Novel blood analysis suggests inflammation ‘plays a role’ in peripartum cardiomyopathy
New serum proteomic analyses suggest that a distinct dysregulation of inflammatory and cholesterol-related pathways drive peripartum cardiomyopathy, a rare but serious complication of pregnancy occurring more frequently among Black women.
In nonischemic cardiomyopathy requiring ICD, Black patients may have worse outcomes
In patients with an implantable cardioverter defibrillator for primary prevention, among those with nonischemic cardiomyopathy, Black patients were more likely to have arrhythmias, to receive ICD therapies and to die than white patients.